There Is Further Upside Potential In Regeneron Pharmaceuticals
- Regeneron Pharmaceuticals is up more than 25% this year.
- The company, along with Sanofi, recently bought priority review voucher for alirocumab FDA submission.
- With the voucher, alirocumab has the chance to beat Amgen’s evolocumab to the market.
- Based on the huge potential for PCSK9 inhibitors and EYLEA sales, which remain on track, Regeneron still has further upside potential.